cmAngio® (V1.6)

The cmAngio® (V1.6) is a Class II Medical Image Management and Processing System designed to precisely identify and localize Breast Arterial Calcification (BAC) on screening mammograms, thereby assisting qualified interpreting physicians. Its methodology involves processing medical images to detect BAC presence, functioning as a non-diagnostic support tool that has achieved substantial equivalence with predicate devices.

The cmAngio® (V1.6) device, developed by CureMetrix, Inc., is a Class II Medical Image Management and Processing System specifically designed to assist qualified interpreting physicians. Its core function is to process screening mammograms to accurately identify Breast Arterial Calcification (BAC), detect its presence at both the study and breast levels, and precisely mark BAC segments on image thumbnails for localization. The U.S. FDA has confirmed that this device is substantially equivalent to legally marketed predicate devices, thereby permitting its commercial marketing, with the clear stipulation that it is not for primary interpretation of breast cancer images or standalone diagnostic decisions. Following its FDA clearance, CureMetrix, Inc. is mandated to adhere to a comprehensive set of ongoing regulatory requirements to maintain compliance. These obligations include general controls such as annual registration, device listing, good manufacturing practices, and specific labeling requirements, alongside prohibitions against misbranding and adulteration. Furthermore, the company must comply with the Quality System (QS) regulation, the Unique Device Identification (UDI) System rule, and medical device reporting for adverse events, ensuring continuous oversight of the device's safety and performance.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What are the specific algorithms or machine learning techniques cmAngio® (V1.6) utilizes to identify and differentiate BAC from other artifacts or breast tissue on mammograms?; Has CureMetrix conducted clinical validation studies to assess the sensitivity, specificity, and positive predictive value of cmAngio® (V1.6) in detecting BAC across diverse patient populations?; How does the integration of cmAngio® (V1.6) into a clinical workflow impact the efficiency of radiologists and the overall turnaround time for mammogram interpretations?; What are the potential clinical implications of widespread BAC detection by cmAngio® (V1.6), particularly concerning its correlation with cardiovascular disease risk?; Are there post-market surveillance plans or real-world data collection initiatives for cmAngio® (V1.6) to monitor its performance and long-term clinical utility?